The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis.
The FDA late Monday approved sales of Trelegy Ellipta, developed jointly by GlaxoSmithKline PLC and Innoviva Inc. It contains three widely used types of medicine to prevent — rather than treat —flare-ups of the life-threatening breathing disorders.
Once daily, patients inhale the medicines through their mouth to open breathing passages and reduce inflammation that can make breathing difficult in people with chronic obstructive pulmonary disease, which includes emphysema and bronchitis.
The disorder worsens over time, requiring patients to add more medicines to prevent flare-ups that can land them in the emergency department — or worse. Many patients use two inhaler types plus other medicines.
An estimated 384 million people worldwide have chronic obstructive pulmonary disease, or COPD, which can make everyday activities such as walking up stairs difficult. It’s usually caused by cigarette smoking or exposure to second-hand smoke, chemical fumes or excess dust in the environment.
U.K.-based GlaxoSmithKline is launching Trelegy with a list price of $530 per month. That’s $146 a month cheaper than the combined prices of two GlaxoSmithKline inhalers that together contain the same three medicines: Incruse Ellipta and Breo Ellipta.
The medicines are an inflammation-reducing steroid called fluticasone furoate, and umeclidinium and vilanterol, drugs that widen narrowed airways and relax their muscles. Common side effects include headaches and other pain, diarrhea, nausea, stomach cramps and cough. Vilanterol and similar drugs carry an increased risk of asthma-related death. Trelegy also can worsen glaucoma and certain infections.
Insurers and prescription benefit managers likely will win significant discounts off the $530 retail price in exchange for covering Trelegy. However, those payers may pass all or much of the savings on to employers and other clients, rather than reducing patients’ out-of-pocket costs.
The product’s approval should help Glaxo rebuild its flagship respiratory medicine business. It was long a leader in the category, thanks to its widely used allergy drugs Flonase and Zyrtec and its Advair inhaler. Flonase and Zyrtec both have generic competition now, and the drugmaker now sells nonprescription versions of them.
Advair, which provided about one-third of Glaxo’s revenue for many years, also has seen increasing competition in recent years. Advair sales are down by more than half since their peak of $8.15 billion in 2011 and are expected to decline to just $1.43 billion by 2020. The Incruse and Breo inhalers, both launched since 2014, have barely made up for one-sixth of that lost revenue.